Drug Approval | August 17, 2024
Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
